Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib.
Nicolas A FraunhofferAnalía Meilerman AbuelafiaMartin BigonnetOdile GayetJulie RoquesEmmanuel TellePatricia Santofimia-CastañoMaría Teresa BorrelloEduardo ChuluyanNelson J DusettiJuan IovannaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
We demonstrate the existence of a carfilzomib-sensitive PDAC subgroup with a specific transcriptomic phenotype that could explain the biological reason for this responsiveness.